Research programme: bromodomain inhibitors - 4SC Discovery/CRELUXAlternative Names: Cancer therapeutics - 4SC Discovery/CRELUX; Epigenetic-modulator inhibitors - 4SC Discovery/CRELUX
Latest Information Update: 29 Apr 2016
At a glance
- Originator 4SC Discovery; CRELUX
- Class Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 Apr 2016 CRELUX has been acquired by WuXi AppTec
- 24 Jul 2014 Early research in Cancer in Germany (unspecified route)